Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Net Cash Flow (2016 - 2025)

Perspective Therapeutics' Net Cash Flow history spans 16 years, with the latest figure at -$2.1 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 91.89% year-over-year to -$2.1 million; the TTM value through Sep 2025 reached -$199.7 million, down 195.87%, while the annual FY2024 figure was $52.2 million, 543.73% up from the prior year.
  • Net Cash Flow for Q3 2025 was -$2.1 million at Perspective Therapeutics, up from -$15.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $132.9 million in Q1 2024 and bottomed at -$164.9 million in Q4 2024.
  • The 5-year median for Net Cash Flow is -$4.5 million (2022), against an average of $926210.5.
  • The largest YoY upside for Net Cash Flow was 7229.81% in 2021 against a maximum downside of 9561.54% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at $37.9 million in 2021, then crashed by 192.18% to -$34.9 million in 2022, then surged by 74.96% to -$8.7 million in 2023, then crashed by 1785.23% to -$164.9 million in 2024, then skyrocketed by 98.73% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Net Cash Flow are -$2.1 million (Q3 2025), -$15.6 million (Q2 2025), and -$17.2 million (Q1 2025).